WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555318
Description: AMG-333 is a potent and selective TRPM8 antagonist for the treatment of migraine. AMG-333 was well-tolerated in 28 day rat and dog preclinical safety studies and advanced to Phase 1 human clinical trials.
MedKoo Cat#: 555318
Chemical Formula: C20H12F5N3O4
Exact Mass: 453.0748
Molecular Weight: 453.32
Elemental Analysis: C, 52.99; H, 2.67; F, 20.95; N, 9.27; O, 14.12
Synonym: AMG-333; AMG 333; AMG333;
IUPAC/Chemical Name: (S)-6-(((3-fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic acid
InChi Key: QEBYISWYMFIXOZ-INIZCTEOSA-N
InChi Code: InChI=1S/C20H12F5N3O4/c21-12-2-1-7-26-17(12)16(10-4-6-15(13(22)8-10)32-20(23,24)25)28-18(29)14-5-3-11(9-27-14)19(30)31/h1-9,16H,(H,28,29)(H,30,31)/t16-/m0/s1
SMILES Code: O=C(O)C1=CN=C(C(N[C@@H](C2=CC=C(OC(F)(F)F)C(F)=C2)C3=NC=CC=C3F)=O)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 453.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
Discovery of TRPM8 Antagonist (S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine
Daniel B. Horne, Kaustav Biswas, James Brown, Michael D. Bartberger, Jeffrey Clarine, Carl D. Davis, Vijay K. Gore, Scott Harried, Michelle Horner, Matthew R. Kaller, Sonya G. Lehto, Qingyian Liu, Vu V. Ma, Holger Monenschein, Thomas T. Nguyen, Chester C. Yuan, Beth D. Youngblood, Maosheng Zhang, Wenge Zhong, Jennifer R. Allen, Jian Jeffrey Chen, and Narender R. Gavva
Publication Date (Web): August 27, 2018 (Article) DOI: 10.1021/acs.jmedchem.8b00518